Page 38 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 38
Chapter 2
with associated costs and patient anxiety [28]. Early data suggest that patients with early failure also show treatment resistance with currently available salvage therapies, and novel, more targeted treatment strategies are clearly needed.
Acknowledgement
The authors wish to acknowledge prof.dr. GJ Ossenkoppele and prof.dr. OS Hoekstra for critically reviewing the manuscript.
36
